New targetable oncogenes in non-small-cell lung cancer

Geoffrey R. Oxnard, Adam Binder, Pasi A. Jänne

Research output: Contribution to journalReview article

227 Citations (Scopus)

Abstract

The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer. A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements. In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclinical data supporting their role in lung cancer, and data on small molecular inhibitors in development.

Original languageEnglish (US)
Pages (from-to)1097-1104
Number of pages8
JournalJournal of Clinical Oncology
Volume31
Issue number8
DOIs
StatePublished - Mar 10 2013
Externally publishedYes

Fingerprint

Oncogenes
Non-Small Cell Lung Carcinoma
Mutation
Insertional Mutagenesis
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Lung Neoplasms
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New targetable oncogenes in non-small-cell lung cancer. / Oxnard, Geoffrey R.; Binder, Adam; Jänne, Pasi A.

In: Journal of Clinical Oncology, Vol. 31, No. 8, 10.03.2013, p. 1097-1104.

Research output: Contribution to journalReview article

Oxnard, Geoffrey R. ; Binder, Adam ; Jänne, Pasi A. / New targetable oncogenes in non-small-cell lung cancer. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 8. pp. 1097-1104.
@article{76e316c3a2b54e78864d03906edf592d,
title = "New targetable oncogenes in non-small-cell lung cancer",
abstract = "The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer. A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements. In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclinical data supporting their role in lung cancer, and data on small molecular inhibitors in development.",
author = "Oxnard, {Geoffrey R.} and Adam Binder and J{\"a}nne, {Pasi A.}",
year = "2013",
month = "3",
day = "10",
doi = "10.1200/JCO.2012.42.9829",
language = "English (US)",
volume = "31",
pages = "1097--1104",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - New targetable oncogenes in non-small-cell lung cancer

AU - Oxnard, Geoffrey R.

AU - Binder, Adam

AU - Jänne, Pasi A.

PY - 2013/3/10

Y1 - 2013/3/10

N2 - The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer. A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements. In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclinical data supporting their role in lung cancer, and data on small molecular inhibitors in development.

AB - The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer. A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements. In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclinical data supporting their role in lung cancer, and data on small molecular inhibitors in development.

UR - http://www.scopus.com/inward/record.url?scp=84875947292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875947292&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.42.9829

DO - 10.1200/JCO.2012.42.9829

M3 - Review article

C2 - 23401445

AN - SCOPUS:84875947292

VL - 31

SP - 1097

EP - 1104

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -